New Crosstex® Antimicrobial Treated Medical Face Mask Effective Against H1N1 (Swine Flu) and Other Influenza A Viruses

NEW CROSSTEX^® ANTIMICROBIAL TREATED MEDICAL FACE MASK IS EFFECTIVE AGAINST H1N1 (SWINE FLU) AND OTHER INFLUENZA A VIRUSES

Crosstex, a division of Cantel Medical Corp. (NYSE: CMN), announces the launch of the Crosstex Ultra Sensitive Medical Face Mask treated with BIOSAFE^® antimicrobial in specific markets outside the United States. The new antimicrobial treated medical mask has been proven effective against H1N1 and other Influenza A strains as well as microorganisms including MRSA, Staphylococcus aureus, VRE, Enterococcus faecalis, Pseudomonas aeruginosa and Salmonella enterica.

“BIOSAFE antimicrobial treatment enhances the superior functional capabilities of the Crosstex Ultra Sensitive Medical Face Mask, providing an unprecedented level of protection,” states Gary Steinberg, CEO of Crosstex. “BIOSAFE antimicrobial chemically binds to the outer mask surface and begins killing the harmful microorganisms upon contact. In fact, testing confirmed that our new medical mask killed between 98.5% and 99.999% of the trapped viruses and bacteria within 5 minutes of contact with the mask,* generating a long-lasting shield that greatly reduces the cross-contamination risk from touching the mask itself. When finished with the mask, the unique water-based antimicrobial composition of BIOSAFE furthermore allows for environmentally safer disposal than with traditional masks and those with other coating agents. The BIOSAFE antimicrobial treated medical mask, like all of our Crosstex Ultra Sensitive Face Masks, is made in the U.S.A. and is latex-free.”

“We developed Ultra Sensitive Medical Face Masks treated with BIOSAFE antimicrobial to address the healthcare industry’s greatest infection control challenges – the current H1N1 pandemic and the growing prevalence of other harmful microorganisms,” states Andrew Whitehead, Vice President of Sales and Marketing at Crosstex. “As one of the largest U.S. manufacturers of face masks, we are proud to take a leading role in adapting advanced infection control technologies to meet the changing needs of today’s health care professionals and their patients.”

The new medical mask is currently being launched in specific markets outside of the United States. Within the United States, the sale of face masks treated with BIOSAFE antimicrobial for medical applications is subject to a 510(k) clearance by the U.S. Food and Drug Administration. At this time Crosstex is awaiting publication of the latest revision of the FDA Guidance Document pertaining to antimicrobial treatments of medical devices prior to the filing of its application. BIOSAFE antimicrobial has passed all U.S. Environmental Protection Agency-required toxicity tests and has an approved EPA label. EPA approval covering the sale of the treated mask in the U.S.A. for non-medical applications is pending.

The Ultra Sensitive Medical Face Mask treated with BIOSAFE antimicrobial is the most recent innovation in a full line of infection control and preventative products from Crosstex, including the Isolator Plus^® N95

Particulate Respirator, a full line of face masks, as well as SaniTyze™ Alcohol-based Hand Sanitizer and disinfectant wipes.

For more information on the Ultra Sensitive Medical Face Mask treated with BIOSAFE antimicrobial, please call Crosstex at 1-888-276-7783 (toll free), or 631-582-6777or visit www.crosstex.com.

*Technical report: An Evaluation of Safety and Efficacy of the Crosstex^® Face Mask Treated With BIOSAFE^® Antimicrobial Agent.
Data on file and available upon request through Crosstex.
BIOSAFE, EPA registered #83019-1.